6533b7d5fe1ef96bd12645ba

RESEARCH PRODUCT

false

subject

0301 basic medicineGanciclovirGeneral Chemical Engineeringmedicine.medical_treatmentDihydroartemisininPharmacology01 natural sciences03 medical and health scienceschemistry.chemical_compoundChloroquineparasitic diseasesmedicineQuinazolineArtemisininbiology010405 organic chemistryPlasmodium falciparumBiological activityGeneral ChemistryAntimicrobialbiology.organism_classificationVirology0104 chemical sciences030104 developmental biologychemistrymedicine.drug

description

Many quinazoline derivatives have been synthesized over the last few decades with great pharmacological potential, such as antimalarial, anti-inflammatory, antimicrobial, anticancer, and antiviral. But so far, no quinazoline–artemisinin hybrids have been reported in the literature. In the present study, five novel quinazoline–artemisinin hybrids were synthesized and evaluated for their in vitro biological activity against malarial parasites (Plasmodium falciparum 3D7), leukemia cells (CCRF-CEM and CEM/ADR5000), and human cytomegalovirus. Remarkably, hybrid 9 (EC50 = 1.4 nM), the most active antimalarial compound of this study, was not only more potent than artesunic acid (EC50 = 9.7 nM) but at the same time more active than the clinically used drugs dihydroartemisinin (EC50 = 2.4 nM) and chloroquine (EC50 = 9.8 nM). Furthermore, hybrids 9 and 10 were the most potent compounds with regard to anticytomegaloviral activity (EC50 = 0.15–0.21 μM). They were able to outperform ganciclovir (EC50 = 2.6 μM), which ...